AC
Aurora Cannabis Inc.
ACB · NASDAQ
$3.82 +1.33% (+$0.05)
1M +5.83%
Market Cap $328.1M
P/E Ratio -
Div. Yield -
ROE 21.00%
Bulios Fair Price
$3.47
9.2% downside
Current Price
$3.82
Undervalued Fair Value Overvalued
According to Bulios Fair Price, ACB is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
100 /100
Cheap P/B 0.62x
P/S 1.13x
EV/EBITDA N/A
Growth
68 /100
Growing Book val. growth 1.50%
Rev. growth 12.82%
FCF growth N/A
Profitability
12 /100
Weak Net margin 38.15%
Op. margin 29.66%
FCF margin 17.57%
Quality
6 /100
Poor ROE 21.00%
ROA 17.83%
Asset turnover 0.47x
Debt
69 /100
Low Current ratio 5.36x
Int. coverage -14.48x
Debt/Equity 0.04x
Stability
29 /100
Unstable Rev. volatility 17.75%
EPS volatility 4,467.05%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about ACB
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Miguel Martin
Employees
1,028
Headquarters
Edmonton
Upcoming events
04 NOV
Earnings
Upcoming earnings report